-
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | US6294441000 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Target Price | 5.25 |
|---|---|
| PE Ratio | None |
| Market Cap | 45M |
| Dividend Yield | 0.0% |
| Beta | 1.02 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NRXP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024